Biotechnology US biotech firm Genzyme, a subsidiary if French drug major Sanofi (Euronext: SAN) has released positive new data from two Phase III studies - ENGAGE and ENCORE - of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1. Both studies, presented on Friday at the 9th Annual Lysosomal Disease Network WORLD Symposium in Orlando, Florida, met their primary efficacy endpoints and together will form the basis of Genzyme's registration package for eliglustat tartrate. 18 February 2013